• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
    • Venture Capital
  • About
  • Contact

AbCellera Receives $175.6 Million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs

May 3, 2020 By admin Leave a Comment

AbCellera’s world-leading drug discovery technology identifies antibodies for potential use in drugs to treat and prevent COVID-19

AbCellera announced today it has received a commitment of up to $175.6 million in support from the Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand efforts related to the discovery of antibodies for use in drugs to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats.

AbCellera’s antibody discovery platform is being used to search blood samples of patients who have recovered from COVID-19 to aid in the discovery of antibodies that can be used to treat and prevent the disease. Since receiving one of the first North American samples from a recovered patient on February 25th, AbCellera has identified over 500 unique human anti-SARS-CoV-2 antibodies as part of a collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health. Antibodies discovered by AbCellera may also be used to create new diagnostic tests to support the medical community in monitoring the spread of COVID-19.

“Our government is mobilizing its resources to confront COVID-19, supporting the researchers and businesses that are working hard to develop medical countermeasures to beat this pandemic. Today’s contribution will support AbCellera Biologics as they use their world-leading technology to rapidly identify solutions for COVID-19 while ensuring Canada’s long-term preparedness for future health challenges,” stated the Honourable Navdeep Bains, Minister of Innovation, Science and Industry.

AbCellera previously announced a partnership with Eli Lilly and Company that seeks to develop a treatment for COVID-19 with the goal of beginning clinical trials in July 2020. As part of the collaboration, Lilly will independently fund and lead clinical development and testing of antibody therapeutics discovered through this partnership.

“Each and every one of us is affected, and our teams stand together, galvanized to fight this outbreak,” said Carl Hansen, Ph.D., CEO of AbCellera. “We are proud to have the support of the Government of Canada to quickly find solutions to the COVID-19 pandemic.”

The Strategic Innovation Fund is quickly deploying support to Canadian companies that are working on large-scale and later-stage promising research and development projects aimed at providing medical countermeasures to COVID-19, including vaccines and critical medical supplies.

In addition to the support from the Government of Canada, AbCellera is receiving support from the City of Vancouver. “The City of Vancouver is fully committed to ensuring AbCellera has the infrastructure needed as they accelerate finding a treatment for COVID-19,” said Mayor Kennedy Stewart, City of Vancouver. “We couldn’t be more proud to be on the front lines of this global effort thanks to the innovation and leadership of AbCellera.”

Phase 1 of the project will improve and apply AbCellera’s world-leading antibody discovery platform to identify fully human antibodies for the potential prevention and treatment of COVID-19 and future pandemics. Phase 2 will build a Good Manufacturing Practice (GMP) facility in Vancouver, BC. This facility will be the first in Canada capable of going from a patient sample to manufacturing antibodies for clinical testing, and will help Canada be prepared to respond to future pandemics.

About the P3 Program

AbCellera has spent the past two years adapting its technology to rapidly respond to pandemics through its participation in the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3). The goal of AbCellera’s four-year, USD $30M P3 project is to establish a robust pandemic response platform that can develop field-ready antibody drugs within 60 days of isolating an emerging viral pathogen.

About AbCellera Biologics Inc.

AbCellera is a privately held Canadian biotech with a drug discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, big data, machine learning, bioinformatics and genomics, identifies new first-in-class drugs and reduces the time it takes to bring treatments to clinic. AbCellera’s partners include leading biotechnology companies, global health organizations and six of the top 10 biopharmaceutical companies. AbCellera was founded in 2012, and completed a Series A financing round in 2018, which was led by DCVC Bio. For more information, visit www.abcellera.com.

Approved for Public Release. Distribution Unlimited.

Contacts

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

The Growing Tin Market: Prospects for Future Demand and Sustainability
Prospects for the Growing Lithium Market in the Coming Years
DevOps and Agile: Integrating Development and Operations
China’s Use of Golden Shares: From Reducing State Role to Quietly Controlling Tech Giants
Why Amazon Acquired One Medical: Disrupting the Healthcare Industry with Technology-Enabled Care
The End of an Era: Why China is No Longer Viable as the World’s Factory
Cloudflare’s FedRAMP authorization opens up a huge market opportunity in the US government sector

Market Research Media

How plunging birthrates threaten national economies
Agile Leadership: Leading Agile Teams for Success
Chinese Brands Reach New Heights of Popularity in the West Amid Growing Political Tensions
Unrestricted Streaming: How VPNs Can Enhance Media Consumption Experience
How the world’s biggest companies have built and defended their moats
Virtual Learning Environments: A Game-Changer in Education?
Streaming video, training, and gaming coming together to form a cohesive and diverse media and entertainment ecosystem

Secondary Sidebar

Tech Events

Upcoming Technology Events of 2023
Space Symposium 2023, April 17-20, Broadmoor, Colorado Springs, Colorado
The Yugabyte’s third annual Distributed SQL Summit (DSS) Asia, March 28, 2023
NVIDIA GTC, a global conference for the era of AI and the metaverse, March 20-23, 2023
Splash User Conference and Partner Summit will take place from April 17 to 20, 2023 in Washington, D.C.

Venture Capital

African Venture Investment Soars to Record High, Fueled by Tech Startups
Pitchly Secures $7 Million Series A Funding for SaaS-Based Data Enablement Solution
Agile Project Management: Roles and Responsibilities
Candidly, a student debt and savings optimization platform, has raised $20.5 million in a Series B round of financing
GameTech Startups Attracting Venture Capital Funding: The Importance of VPN Security

Footer

Recent Posts

  • Hydrogen Technology: The Key to a Sustainable Future for the Cruise and Shipping Industries
  • Regenerative Finance: Shifting Towards Sustainable and Equitable Financial Systems
  • Why Arm Ltd May Build Its Own Semiconductor
  • Dragonfly Announces New Kubernetes Operator for In-Memory Datastore for Simplified Operations and Increased Performance
  • Cosmic Crops Return: Seeds Sent to Space to Develop Resilient Crops for a Warming World
  • AI Developer
  • Nvidia’s Lead in AI: Disrupting the Tech Industry
  • Canva Launches Brand Management Features and AI-Powered Design Tools to Empower Creatives and Professionals
  • Cloudflare Enters Fraud Detection Market with Cloudflare Fraud Detection
  • Devices utilizing Wi-Fi HaLow technology are gaining momentum

App Coding

Understanding Data Structures and Algorithms
Browser Innovation: The Rise of Progressive Web Apps (PWA)
Appy Pie Introduces AI App Generator to Expedite App Development Process
How to Build a Successful Social Media App: Best Practices and Key Considerations
App Quality Assurance: Best Practices for Testing Mobile Apps

API Coding

How to built a gaming API
Leveraging API and IP Intelligence for Improved Cybersecurity
How to code an API with ChatGPT
Building More Resilient APIs through Negative Testing
Using OpenAI ChatGPT API with Java

Blockchaining

What is Web3?
Highlights: Blockchain Conference in Tel Aviv
Building a Decentralized VPN Using Blockchain Technology
The Role of Blockchain in Digital Identity Management
How safe is blockchain technology behind cryptocurrencies

Event Calendar

PCIM Europe 2023, May 9-11, 2023, Nuremberg Exhibition Center, Nuremberg, Germany
Interwire Trade Exposition, May 9-11, 2023, Georgia World Congress Center, Atlanta, GA
ProMat 2023, the leading trade show for the manufacturing and supply chain industry, March 20-23 2023, Chicago’s McCormick Place
Prints 2023, Printing Conference, March 3, 2023
Milan Design Week 2023, April 17-23 2023, Milan, Italy

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT